IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Files An 8-K Financial Statements and Exhibits
Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

Immune Design Corp. Exhibit
EX-99.1 2 exhibit991oct17pres.htm EXHIBIT 99.1 Exhibit Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial for CMB305 in Synovial Sarcoma Patients•CMB305 Monotherapy vs. Placebo in the Maintenance Setting•PFS Analysis for Potential Full Approval as Early as 24 Months After Study Start•Conference Call and Webcast Tomorrow at 5:30am PT/8:30am ETSEATTLE and SOUTH SAN FRANCISCO,…
To view the full exhibit click here

About IMMUNE DESIGN CORP. (NASDAQ:IMDZ)

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA).